19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities

drug approval expired 90% Health

BrightGene Bio-Medical has reported significant results from a Phase III clinical trial of its GLP-1/GIP dual receptor agonist, BGM0504, which showcased impressive reductions in various health indicators such as weight and triglycerides. The results are expected to contribute to advancements in cardiometabolic health management.

🇨🇳 Location: Suzhou — Sources: 6 — First seen: — Last seen:
BrightGene Bio-Medical clinical trial health GLP-1 cardiometabolic

Linked Entities

BrightGene Bio-Medical Technology Co., Ltd.

organization involved

Contributing Articles